<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities center on non-hormonal NK therapies, transdermal delivery, virtual care and underserved regions, fueled by aging demographics and pharma investment despite safety and access barriers.Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/6265231/vasomotor-symptoms-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=7wzhkf&amp;utm_campaign=2330848+-+Vasomotor+Symptoms+2026-2031+-+Growing+Demand+for+Non-Hormonal+Menopause+Treatments+Drives+Market+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Vasomotor Symptoms - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Vasomotor Symptoms - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. Vasomotor Symptoms Market to Reach USD 6.4 Billion by 2031 as Demand for Non-Hormonal Menopause Treatments Accelerates The global vasomotor symptoms market was valued at USD 4.2 billion in 2025 and is expected to increase from USD 4.5 billion in 2026 to USD 6.4 billion by 2031. The market is projected to register a compound annual growth rate of 7.4% from 2026 to 2031, supported by an expanding postmenopausal population, increased pharmaceutical investment in women's health, and the introduction of targeted non-hormonal therapies. Expanding Postmenopausal Population Supports Market Growth Demographic trends continue to create sustained demand across the vasomotor symptoms treatment market. More than 1 billion women were postmenopausal in 2025, and the World Health Organization expects this population to reach 1.2 billion by 2030. With up to 80% of women experiencing vasomotor symptoms during the menopausal transition, the growing population is adding to a substantial and historically undertreated patient base. Growth opportunities are particularly significant in lower- and middle-income countries, where access to menopause care remains limited compared with developed markets. Greater awareness, improved clinical education, telehealth expansion, and stronger women's health programs could help address diagnosis and treatment gaps in these regions. Pharmaceutical Investment Strengthens the Women's Health Pipeline Pharmaceutical companies are increasing their focus on the vasomotor symptoms market through acquisitions, regulatory approvals, and late-stage clinical development. Sun Pharmaceutical Industries announced its planned USD 11.75 billion acquisition of Organon &amp; Co. in April 2026, combining women's health portfolios with commercial reach across more than 140 countries. Bayer expanded the commercial presence of elinzanetant through approvals in the United Kingdom, the United States, and the European Union during 2025. Astellas also reported positive Phase 3 results for fezolinetant in Japan in 2026, supporting continued development across major international markets. These investments are expected to strengthen product launches, regulatory activity, physician engagement, and payer negotiations. Safety Monitoring Remains a Key Market Restraint Hepatic safety concerns associated with certain neurokinin-targeted therapies may affect prescribing decisions and patient adherence. The U.S. Food and Drug Administration issued a safety communication concerning fezolinetant in September 2024 and added a boxed warning in December 2024 following postmarketing reports of serious liver injury. Current protocols require liver function testing before treatment, monthly testing during the first three months, and additional assessments at months six and nine. European regulators also issued healthcare professional communications in 2025. Although elinzanetant demonstrated a more favorable hepatic profile in the OASIS trials, long-term safety evidence will remain important to confidence in this emerging treatment class. Other factors influencing the vasomotor symptoms market include rapid approvals of neurokinin-3 receptor antagonists, employer-sponsored menopause benefits, virtual menopause clinics, and AI-enabled precision dosing. Constraints include limited reimbursement outside developed markets, cultural stigma, and regulatory uncertainty surrounding botanical supplements. Hormonal Treatments Retain Market Leadership Hormonal treatments accounted for 68.4% of the vasomotor symptoms market in 2025. Their leadership reflects extensive clinical use, physician familiarity, established reimbursement pathways, and evidence demonstrating significant reductions in symptom frequency. Estrogen-only therapies are commonly used for women without a uterus, while estrogen-progesterone combinations remain important for women with an intact uterus. Non-hormonal treatments are forecast to grow at a 10.8% CAGR through 2031, making them the fastest-growing treatment category. Expansion is being driven by targeted therapies such as fezolinetant and elinzanetant, particularly for patients who cannot or prefer not to use hormonal therapy. SSRIs, SNRIs, and other established non-hormonal options will continue to serve selected patients, while herbal and dietary supplements face regulatory and product differentiation challenges. Oral Therapies Lead as Transdermal Formulations Gain Momentum Oral administration represented 56.5% of the market in 2025, supported by widespread use of oral hormone therapy and once-daily neurokinin-targeted treatments. Familiar prescribing, counseling, and refill practices also reinforce the position of tablet-based therapies. Transdermal gels and sprays are projected to grow at an 8.8% CAGR through 2031. Their growth is supported by steady hormone exposure and increasing clinical interest in delivery routes that bypass first-pass hepatic metabolism. Transdermal patches, injectable products, and topical formulations will continue to address specific patient and clinical requirements. Regional Vasomotor Symptoms Market Outlook North America held 41.9% of the global market in 2025, making it the leading region. Strong specialist access, early adoption of new treatments, established reimbursement systems, and employer-sponsored menopause programs support regional demand. Safety-monitoring requirements for fezolinetant have added complexity but have not diminished broader commercial interest in non-hormonal menopause care. Europe remains the second-largest regional market. Regulatory approvals and reimbursement reviews continue to shape access, including the European Commission's November 2025 approval of elinzanetant for menopause-associated vasomotor symptoms and symptoms related to endocrine therapy for breast cancer. Reimbursement differences between European countries may continue to produce uneven adoption. Asia-Pacific is forecast to record the fastest regional growth, with a 10.5% CAGR through 2031. Positive Phase 3 fezolinetant results in Japan and expanding menopause-care services in Australia support this outlook. However, provider education gaps and cultural stigma continue to limit care-seeking in parts of Asia, the Middle East, and Africa. Future growth in South America will depend on improved access pathways, stronger reimbursement, and broader engagement with women's health services. Key Topics Covered: 1 INTRODUCTION 1.1 Study Assumptions and Market Definition 1.2 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET LANDSCAPE 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rise in Post-Menopausal Female Population Base 4.2.2 Growing Pharmaceutical Investment in Women's Health Portfolios 4.2.3 Rapid Approvals of Neurokinin-3 Receptor Antagonists 4.2.4 Employer Adoption of Menopause Benefits Platforms 4.2.5 AI-Enabled Precision Dosing and Companion Diagnostics 4.2.6 Expansion of Tele-Menopause Virtual Clinics in Underserved Regions 4.3 Market Restraints 4.3.1 Long-Term Hepatic Safety Concerns for NK-3 Antagonists 4.3.2 Limited Reimbursement Outside OECD Markets 4.3.3 Cultural Stigma Suppressing Care-Seeking in Asia and Middle East and Africa 4.3.4 Regulatory Ambiguity for Botanical OTC Supplements 4.4 Supply-Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces Analysis 4.7.1 Bargaining Power of Suppliers 4.7.2 Bargaining Power of Buyers 4.7.3 Threat of New Entrants 4.7.4 Threat of Substitutes 4.7.5 Intensity of Competitive Rivalry 5 MARKET SIZE AND GROWTH FORECASTS 5.1 By Treatment Type 5.1.1 Hormonal Treatment 5.1.1.1 Estrogen 5.1.1.2 Progesterone 5.1.1.3 Estrogen-Progesterone Combination 5.1.2 Non-Hormonal Treatment 5.1.2.1 NK-3 Receptor Antagonists 5.1.2.2 SSRIs 5.1.2.3 SNRIs 5.1.2.4 Gabapentinoids 5.1.2.5 Herbal and Dietary Supplements 5.2 By Route of Administration 5.2.1 Oral 5.2.2 Transdermal Patch 5.2.3 Transdermal Gel and Spray 5.2.4 Parenteral, Injectable 5.2.5 Topical, Vaginal and Derma 5.3 By Distribution Channel 5.3.1 Hospital Pharmacies 5.3.2 Retail Pharmacies 5.3.3 Online Pharmacies 5.4 By Menopausal Stage 5.4.1 Perimenopause 5.4.2 Early Post-Menopause, Less Than 5 Years 5.4.3 Late Post-Menopause, More Than 5 Years 5.5 Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 APAC 5.5.3.1 China 5.5.3.2 India 5.5.3.3 Japan 5.5.3.4 Australia 5.5.3.5 South Korea 5.5.3.6 Rest of APAC 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Strategic Moves 6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments) 6.4.1 AbbVie Inc. 6.4.2 Astellas Pharma Inc. 6.4.3 Bayer AG 6.4.4 Besins Healthcare 6.4.5 Cipla Ltd. 6.4.6 Eisai Co. Ltd. 6.4.7 Endoceutics Inc. 6.4.8 Ferring Pharmaceuticals 6.4.9 Fervent Pharmaceuticals 6.4.10 Hisamitsu Pharmaceutical Co. 6.4.11 KaNDy Therapeutics 6.4.12 Knight Therapeutics Inc. 6.4.13 Lupin Ltd. 6.4.14 Mithra Pharmaceuticals 6.4.15 Novo Nordisk A/S 6.4.16 Organon and Co. 6.4.17 Pfizer Inc. 6.4.18 Sun Pharma Industries Ltd. 6.4.19 Teva Pharmaceutical Industries Ltd. 6.4.20 Theramex 6.4.21 Viatris Inc. 7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK 7.1 White-Space and Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6265231/vasomotor-symptoms-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=7wzhkf&amp;utm_campaign=2330848+-+Vasomotor+Symptoms+2026-2031+-+Growing+Demand+for+Non-Hormonal+Menopause+Treatments+Drives+Market+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/gbhnba</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MzMyNmI2NzctNmNmMy00NGMyLWJmNDUtMjRjNjRiZTI5NjJiLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Vasomotor Symptoms 2026-2031 - Growing Demand for Non-Hormonal Menopause Treatments Drives Market Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn